Menu
Stemline logo.
Stemline Therapeutics announced its contract pharmacy restrictions for Orserdu will take effect May 18.

Stemline Therapeutics 41st Drugmaker to Enact 340B Contract Pharmacy Restrictions

Shannon Young, Associate Editor/Senior Writer 340B Report Views
A New York-based drugmaker recently announced new contract pharmacy restrictions for covered entities looking to purchase a breast cancer treatment [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Readiness Over Reaction

Bergman, Ruiz to Introduce Bipartisan Bill Exempting Additional Covered Entities From 340B Rebates

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live